Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects double-digit top-line growth, targeting around 13% to 16% CAGR going forward (Pages 7, 9, 18). EBITDA margin is expected to improve gradually, with a steady-state margin around 33% annually, up from 29% in FY'23 and 33% in FY'24 (Pages 9, 18). Margin expansion is anticipated as growth picks up, especially with improvements expected from the US business and product mix (Pages 7, 8, 18). Earnings growth driven by increased revenues, better product mix, strong cost control, and higher other income as noted in recent quarters (Pages 4, 5, 9). New R&D investments (~₹30-40 crores

Current/ Expected Orderbook/ Pending Orders?

The company does not maintain a formal order book or pending orders. Business operates on an order-to-order basis based on customer needs and market demand. It is difficult to predict exact revenue numbers or future order flow quarter-to-quarter. Customers and orders are somewhat known but there is no structured long-term contract backlog. This approach reflects the nature of the enzyme and bioproducts industry, which is demand-driven and flexible.

Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. The company has about ₹500 crores of cash on the balance sheet and generates around ₹100 crores of cash annually. Capital allocation strategy includes dividends and keeping cash reserves for potential opportunities and business expansion. The company is also investing around ₹30-40 crores over the next two years in developing new R&D centers. No specific plans or announcements related to raising debt or equity funding were discussed in the call.

Any current/future capex/capital investment/strategic investment?

Advanced Enzyme Technologies is investing in a new R&D center in Nasik (Pathardi area) on a 15-acre land acquired during COVID times. The R&D building being constructed is around 120,000 square feet, approximately three times their current R&D capacity. Planned R&D capital expenditure for the next two years is ₹30-40 crores. The company is keeping cash reserves (~₹500 crores) available for potential strategic investments or business expansion opportunities. Capital allocation includes continuous investments in R&D setup along with normal capital expenditures. Mukund Kabra indicated expansion p

IN US

Sale is live|00:00:00left today

Advanced Enzyme Technologies LtdQ1 FY24Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹374P/E: 25.4Market Cap: ₹4.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Future growth expectations for Advanced Enzyme Technologies Limited: - **Overall top-line growth:** Expected between 13% to 16% for FY'25 (Page 8, 18). - **Human nutrition segment:** Anticipated to grow with continued contributions from the US and domestic markets; expected to stabilize between 65%-70% of total business mix over the next 2-3 years (Pages 7, 18). - **US market:** Growth driven by new products in weight and sugar management with 9% growth in FY'24 and positive outlook for FY'25 (Pages 8, 18). - **Bioprocessing segment:** Grew 21% in FY'24; expected decent growth due to new product launches (Page 4, 14). - **Animal nutrition:** Volatile with challenges; 5% decline in FY'24, but expected to stabilize with industry dynamics (Pages 4, 16, 18). - **Product pipeline and R&D:** Significant investment in new R&D facilities (~₹30-40 crores over two years) to drive future innovation and growth (Page 16). - **Probiotics business:** Growth potential linked to combined enzyme-probiotics formulations, though specific targets are unclear (Page 18).

Margin guidance

Category 3

→The company expects double-digit top-line growth, targeting around 13% to 16% CAGR going forward (Pages 7, 9, 18).
→EBITDA margin is expected to improve gradually, with a steady-state margin around 33% annually, up from 29% in FY'23 and 33% in FY'24 (Pages 9, 18).
→Margin expansion is anticipated as growth picks up, especially with improvements expected from the US business and product mix (Pages 7, 8, 18).
→Earnings growth driven by increased revenues, better product mix, strong cost control, and higher other income as noted in recent quarters (Pages 4, 5, 9).
→New R&D investments (~₹30-40 crores over two years) and product pipeline expansion expected to support sustainable growth (Page 16).
→Probiotics and other high-potential areas expected to contribute, though precise margin impact is unclear (Page 18).
→The animal nutrition segment may see normal pharma-industry-like growth but remains challenging due to competitive pressures (Page 16).

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or planned fundraising through debt or equity.
→The company has about ₹500 crores of cash on the balance sheet and generates around ₹100 crores of cash annually.
→Capital allocation strategy includes dividends and keeping cash reserves for potential opportunities and business expansion.
→The company is also investing around ₹30-40 crores over the next two years in developing new R&D centers.
→No specific plans or announcements related to raising debt or equity funding were discussed in the call.

Order book

→The company does not maintain a formal order book or pending orders.
→Business operates on an order-to-order basis based on customer needs and market demand.
→It is difficult to predict exact revenue numbers or future order flow quarter-to-quarter.
→Customers and orders are somewhat known but there is no structured long-term contract backlog.
→This approach reflects the nature of the enzyme and bioproducts industry, which is demand-driven and flexible.

Capex plans

Yes

→Advanced Enzyme Technologies is investing in a new R&D center in Nasik (Pathardi area) on a 15-acre land acquired during COVID times.
→The R&D building being constructed is around 120,000 square feet, approximately three times their current R&D capacity.
→Planned R&D capital expenditure for the next two years is ₹30-40 crores.
→The company is keeping cash reserves (~₹500 crores) available for potential strategic investments or business expansion opportunities.
→Capital allocation includes continuous investments in R&D setup along with normal capital expenditures.
→Mukund Kabra indicated expansion plans will be triggered when capacity utilization reaches around 80%, with a current utilization of about 65%.
→Expansion will be done gradually in small increments to scale quickly as demand grows.

How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Advanced Enzyme Technologies Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Advanced Enzyme Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio